Peter Senter will discuss Empowered Antibodies for Cancer Therapy. The technology surrounding antibody drug conjugates has advanced significantly in the past two years, with developments in antibody, drug, linker and conjugation technologies. This presentation will overview some of the recent technical achievements surrounding antibody drug conjugates, and includes the development of a clinically approved drug.
Peter Senter joined Seattle Genetics in August 1998 and has served as Vice President, Chemistry since September 2002. In February 2009, Dr. Senter was recognized as the company's first Distinguished Fellow. He leads Seattle Genetics' chemistry department, which carries out research in antibody-drug conjugate technologies, including the development of potent drug payloads, novel linker systems, conjugation methodology and mechanism of action studies. Prior to joining the company, Dr. Senter was with Cytokine Networks, Inc., the Bristol-Myers Squibb Pharmaceutical Research Institute and the Dana-Farber Cancer Institute, Harvard Medical School. Dr. Senter received a Ph.D. in Chemistry from the University of Illinois, and an A.B. in Biochemistry from the University of California, Berkeley. He is the Senior Editor of Bioconjugate Chemistry and serves on the Editorial Board of four scientific journals. Dr. Senter is an Affiliate Professor of Bioengineering at the University of Washington. His research interests include targeted drug delivery, protein chemistry and biochemistry, and anti-cancer drug design. Dr. Senter has authored more than 100 scientific publications and holds more than 20 patents.
Additional companies presenting include:
PfizerWorldwide Research & Development
University of Pennsylvania
Merrimack Pharmaceuticals, Inc
Fox Chase Cancer Center
Oxford Biotherapeutics, Inc.
Memorial Sloan-Kettering Cancer Center
Molecular Partners AG
Amgen Research (Munich) GmbH
Regeneron Pharmaceuticals, Inc.
Affimed Therapeutics AG
University of Stanford
As part of the Molecular Med TRI-CON 2013, attendees have access to a partnering forum, 5 symposia, 18 short courses, and 12 core programs. The event attracts than 3,000 attendees and provides attendees an opportunity to interact with each other in the shared exhibit/poster hall, plenary keynotes and social functions.
Registration discounts are available until January 11, 2013. For complete event details visit: http://www.triconference.com/
To inquire about sponsoring and/or exhibiting, contact Jon Stroup, 781-972-5483, email@example.com.
Writers and editors are encouraged to attend. To request a press pass, contact Lisa Scimemi at firstname.lastname@example.org.
About Cambridge Healthtech Institute (www.chicorporate.com)
Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.
Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.